ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy

. 2025 Aug;32(8):5434-5435.

doi: 10.1245/s10434-025-17458-8. Epub 2025 May 21.

Kojiro Omiya¹, Atsushi Oba^#^{2

3

4}, Kota Sugiura¹, Aya Maekawa^{1

5}, Takafumi Mie⁶, Kosuke Kobayashi¹, Yoshihiro Ono¹, Hiromichi Ito¹, Yosuke Inoue¹, Yu Takahashi^#⁷

Affiliations

¹ Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
² Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. atsushi.oba@jfcr.or.jp.
³ Department of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan. atsushi.oba@jfcr.or.jp.
⁴ Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. atsushi.oba@jfcr.or.jp.
⁵ Department of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan.
⁶ Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
⁷ Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. yu.takahashi@jfcr.or.jp.

^# Contributed equally.

Kojiro Omiya et al. Ann Surg Oncol. 2025 Aug.

. 2025 Aug;32(8):5434-5435.

doi: 10.1245/s10434-025-17458-8. Epub 2025 May 21.

Kojiro Omiya¹, Atsushi Oba^#^{2

3

4}, Kota Sugiura¹, Aya Maekawa^{1

5}, Takafumi Mie⁶, Kosuke Kobayashi¹, Yoshihiro Ono¹, Hiromichi Ito¹, Yosuke Inoue¹, Yu Takahashi^#⁷

¹ Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
² Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. atsushi.oba@jfcr.or.jp.
³ Department of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan. atsushi.oba@jfcr.or.jp.
⁴ Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. atsushi.oba@jfcr.or.jp.
⁵ Department of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan.
⁶ Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
⁷ Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. yu.takahashi@jfcr.or.jp.

^# Contributed equally.

No abstract available

Conflict of interest statement

DISCLOSURES: There are no conflicts of interest.

ASO Author Reflections: A New Proposal for Therapeutic Strategies in Patients with High-Grade Pancreatic Intraepithelial Neoplasia at the Pancreatic Transection Margin in Pancreatic Ductal Adenocarcinoma.
Kobayashi K, Sawada Y, Sahara K, Kikuchi Y, Miyake K, Yabushita Y, Homma Y, Kumamoto T, Matsuyama R, Endo I. Kobayashi K, et al. Ann Surg Oncol. 2025 Aug;32(8):5432-5433. doi: 10.1245/s10434-025-17508-1. Epub 2025 May 28. Ann Surg Oncol. 2025. PMID: 40437337 No abstract available.

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (version 3. 2024). Retrieved Accessed 15 December 2024. at https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf .
1. Oba A, Del Chiaro M, Satoi S, et al. New criteria of resectability for pancreatic cancer: a position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). J Hepatobiliary Pancreat Sci. 2022;29:725–31. - DOI - PubMed
1. Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18:2–11. - DOI - PubMed
1. Omiya K, Oba A, Sugiura K, et al. Resectable pancreatic cancer with CA19-9 >500 U/mL: a biological indicator for survival benefit with intensive neoadjuvant chemotherapy. Ann Surg Oncol. 2025. https://doi.org/10.1245/s10434-025-17407-5 . - DOI - PubMed
1. Omiya K, Oba A, Inoue Y, et al. Serum DUPAN-2 could be an alternative biological marker for CA19-9 nonsecretors with pancreatic cancer. Ann Surg. 2023;277:e1278–83. - DOI - PubMed